FTIH study to assess safety and tolerability of PP 1420

• Research type

  Research Study

• Full title

  A First-Time-in-Human, Double-Blind, Randomised, Placebo-Controlled Dose Escalation Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects.

• IRAS ID

  41812

• Contact name

  Stephen R Bloom

• Sponsor organisation

  Imperial College London

• Eudract number

  2009-017522-39

• ISRCTN Number

  isrctn

• Research summary

  When humans eat, the bowels naturally secrete chemicals into the bloodstream which make people feel full and hence stop eating. One of these chemicals is known as "Pancreatic Polypeptide" (PP). We have previously shown that injections of PP reduce appetite and food intake in human volunteers. We have now developed a long acting version of PP, called PP 1420, as a treatment for obesity. PP 1420 has been tested in animals and has been shown to be safe, and to reduce their appetite. This study will test the safety and tolerability of PP 1420 for the first time in humans.

• REC name

  London - Harrow Research Ethics Committee

• REC reference

  10/H0709/10

• Date of REC Opinion

  3 Mar 2010

• REC opinion

  Further Information Favourable Opinion